Evidence map›Paper›PMID 37026591›Full record

ArticleJournal of medicinal chemistry2023

Discovery of an

Alice C Harnden, Owen A Davis, Gary M Box, Angela Hayes, Louise D Johnson, Alan T Henley, Alexis K de Haven Brandon, Melanie Valenti, Kwai-Ming J Cheung, Alfie Brennan and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Design and synthesis of novelFuture medicinal chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 1 institution in 1 country.

Owen A Davis
Gary M Box
Angela Hayes
Louise D Johnson
Alan T Henley
Alexis K de Haven Brandon
Melanie Valenti
Kwai-Ming J Cheung
Alfie Brennan
Rosemary Huckvale
Olivier A Pierrat
Rachel Talbot
Michael D Bright
Hafize Aysin Akpinar
Daniel S J Miller
Dalia Tarantino
Sharon Gowan
Selby de Klerk
Peter Craig McAndrewORCID 0000-0002-1366-088X
Yann-Vaï Le BihanORCID 0000-0002-6850-9706
Mirco Meniconi
Rosemary Burke
Vladimir Kirkin
Rob L M van Montfort
Florence I RaynaudORCID 0000-0003-0957-6279
Olivia W Rossanese
Benjamin R BellenieORCID 0000-0001-9987-3079
Institute of Cancer Research · GB

Funding

Cancer Research UK C309/A11566
6 · The paper itself

Abstract

B-cell lymphoma 6 (BCL6) is a transcriptional repressor and oncogenic driver of diffuse large B-cell lymphoma (DLBCL). Here, we report the optimization of our previously reported tricyclic quinolinone series for the inhibition of BCL6. We sought to improve the cellular potency and

Indexed as

Lymphoma, Large B-Cell, DiffuseQuinolonesAnimalsCell Line, TumorDisease Models, AnimalFluorine CompoundsHumansMiceProto-Oncogene Proteins c-bcl-6Transcription FactorsBCL6 protein, humanBcl6 protein, mouseCCT373566Fluorine CompoundsProto-Oncogene Proteins c-bcl-6QuinolonesTranscription Factors

Identifiers

PMID37026591
PMCPMC10150366
OpenAlexW4362691842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.